Drug Profile
Ianalumab - MorphoSys/Novartis
Alternative Names: NOV-5; NVP-VAY736; VAY-736Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator MorphoSys; Novartis
- Developer H. Lee Moffitt Cancer Center and Research Institute; MorphoSys; Novartis
- Class Antifibrotics; Antineoplastics; Antirheumatics; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Advanced glycosylation end product modulators; Antibody-dependent cell cytotoxicity; B-cell activation factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura; Lupus nephritis; Sjogren's syndrome; Systemic lupus erythematosus
- Phase II/III Autoimmune hepatitis
- Phase II Idiopathic pulmonary fibrosis; Multiple sclerosis; Pemphigus vulgaris; Rheumatoid arthritis
- Phase I Non-Hodgkin's lymphoma
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 05 Mar 2024 Novartis plans a phase II pharmacokinetic and safety trial for Systemic lupus erythematosus, Rheumatoid arthritis, and Sjogren's syndrome (SC) in July 2024 (NCT06293365)
- 08 Feb 2024 Novartis intends to file a regulatory application for Autoimmune haemolytic anaemia and Idiopathic thrombocytopenic purpura in 2026 (Novartis pipeline, February 2024)
- 18 Nov 2023 Novartis Pharmaceuticals plans a phase III SIRIUS-SLE LTE trial for Systemic lupus erythematosus (In adults, In children, In adolescents, In the elderly, Treatment-experienced) in May 2024 (SC) (NCT06133972)